SILKIS OINTMENT
Land: Kanada
Språk: engelska
Källa: Health Canada
Produktens egenskaper
(SPC)
17-10-2017
Vissa dokument för denna produkt är för närvarande inte tillgängliga, du kan skicka en begäran till vår kundservice och vi kommer att meddela dig så snart vi kan få dem.
Skicka förfrågan.
Skicka förfrågan.
Aktiva substanser:
CALCITRIOL
Tillgänglig från:
GALDERMA CANADA INC
ATC-kod:
D05AX03
INN (International namn):
CALCITRIOL
Dos:
3MCG
Läkemedelsform:
OINTMENT
Sammansättning:
CALCITRIOL 3MCG
Administreringssätt:
TOPICAL
Enheter i paketet:
5G/30G/60G/100G
Receptbelagda typ:
Prescription
Terapiområde:
MISC. SKIN AND MUCOUS MEMBRANE AGENTS
Produktsammanfattning:
Active ingredient group (AIG) number: 0113628006; AHFS:
Bemyndigande status:
APPROVED
Tillstånd datum:
2009-12-01
Produktens egenskaper
PRODUCT MONOGRAPH
Pr
SILKIS
®
(Calcitriol)
Ointment
3 µg/g
Topical Non-Steroidal
Antipsoriatic Agent
GALDERMA CANADA INC.
55 Commerce Valley Drive W., Suite 400
Thornhill, ON
L3T 7V9
www.galderma.ca
DATE OF PREPARATION:
November 30, 2009
DATE OF REVISION:
October 17, 2017
SUBMISSION CONTROL NO: 206311
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................
3
CONTRAINDICATIONS
...................................................................................................
3
WARNINGS AND PRECAUTIONS
.................................................................................
4
ADVERSE REACTIONS
...................................................................................................
5
DRUG INTERACTIONS
...................................................................................................
7
DOSAGE AND ADMINISTRATION
...............................................................................
7
OVERDOSAGE
..................................................................................................................
8
ACTION AND CLINICAL PHARMACOLOGY
.............................................................. 8
STORAGE AND STABILITY
...........................................................................................
9
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................... 9
PART II: SCIENTIFIC INFORMATION
................................................................................10
PHARMACEUTICAL INFORMATION
..........................................................................10
CLINICAL TRIALS
..........................................................................................................
10
DETAILED PHARMACOLOGY
......................................
Läs hela dokumentet
